Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 10/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615171 | 0.88 | MEN1 (0.48) | PKMPGRLMNAMAPTALDH1A1 | |
| SCHEMBL13852820 | 0.86 | PKM (0.73) | PKMPGRLMNAMAPTTDP1 | |
| SCHEMBL13852843 | 0.86 | KMT2A (0.53) | PKMPGRLMNAMAPTALDH1A1 | |
| SCHEMBL13615120 | 0.85 | CES1 (0.57) | PKMLMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL13615168 | 0.84 | HSD17B2 (0.61) | PGRMAPTHSD17B2KMT2AMEN1 | |
| SCHEMBL16325530 | 0.83 | PKM (0.77) | PKMPGRLMNAMAPTTDP1 | |
| SCHEMBL13852797 | 0.82 | PGR (0.63) | PKMPGRLMNAMAPTTDP1 | |
| SCHEMBL13615138 | 0.82 | PGR (0.58) | PGRLMNAALDH1A1KDRAURKB | |
| SCHEMBL13615209 | 0.82 | ALDH1A1 (0.50) | PKMLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL13615225 | 0.81 | PPARG (0.55) | LMNAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | PKM 513/4885PGR 1506/4885LMNA 2891/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | PKM 446/4885PGR 1648/4885LMNA 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.